BSX Stock — Boston Scientific Corp.

Boston Scientific Corp. (BSX)

Updated October 16, 2026.

BSX is a Stock. Total return is 936.8% over the past 34.4 years.

Boston Scientific Corporation develops and manufactures medical devices for interventional procedures across cardiology, gastroenterology, urology, and neuromodulation, serving global healthcare markets. The company does not currently have an established dividend distribution program. This equity security may appeal to growth-oriented investors seeking exposure to the medical device sector.

BSX performance

Price and return data through 2026-10-16.

Total return is 936.8% over the past 34.4 years. Over the past year its total return — price change plus distributions reinvested — is -54.6%. Its deepest 1-year drawdown was 60.4%.

BSX key facts

Asset type

Stock

Asset class

Equity

Inception date

05/19/1992

Distribution frequency

None

Last close

$44.39 (as of 2026-10-16)

Market cap

$64,331,298,659

Average volume

12408372.0

Beta

0.575

Payout ratio

0.0%

P/E ratio

17.97

Forward P/E

13.2275

EPS

$2.47

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BSX risks and drawbacks

The deepest 1-year drawdown on record here is 60.4%.

Who may consider BSX — and who may not

It is a weaker fit for investors who need monthly cash flow (BSX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BSX

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions